Vasconcellos Jaqueline Barbeito de, Pereira Daniele do Nascimento, Vargas Thiago Jeunon de Sousa, Levy Roger Abramino, Pinheiro Geraldo da Rocha Castelar, Cursi Ígor Brum
Universidade do Estado do Rio de Janeiro (Uerj) - Rio de Janeiro (RJ), Brazil.
Hospital Geral de Bonsucesso (HGB) - Rio de Janeiro (RJ), Brazil.
An Bras Dermatol. 2016 Sep-Oct;91(5 suppl 1):137-139. doi: 10.1590/abd1806-4841.20164456.
The use of tumor necrosis factor antagonists (anti-TNF) has become a usual practice to treat various inflammatory diseases. Although indicated for the treatment of psoriasis, anti-TNF may paradoxically trigger a psoriasiform condition. We present a case of a female patient who, during the use of infliximab for rheumatoid arthritis, developed psoriasis. In an attempt to switch anti-TNF class, we observed a cumulative worsening of the lesions requiring suspension of the immunobiological agent and the introduction of other drugs for clinical control. The therapeutic challenge of this paradoxical form of psoriasis is the focus of our discussion. The use of another anti-TNF in these patients is a matter of debate among experts.
使用肿瘤坏死因子拮抗剂(抗TNF)已成为治疗各种炎症性疾病的常用方法。尽管抗TNF被用于治疗银屑病,但矛盾的是,它可能引发银屑病样病症。我们报告一例女性患者,在使用英夫利昔单抗治疗类风湿性关节炎期间出现了银屑病。为尝试更换抗TNF类别,我们观察到皮损逐渐恶化,需要停用这种免疫生物制剂并引入其他药物进行临床控制。这种矛盾形式的银屑病的治疗挑战是我们讨论的焦点。在这些患者中使用另一种抗TNF在专家中存在争议。